TIDMFDBK
RNS Number : 2540T
Feedback PLC
24 March 2021
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR") (which forms part of Domestic UK Law pursuant
to the European Union (Withdrawal) Act 2018). With the publication
of this announcement, this information is now considered to be in
the public domain.
Feedback plc
Bleepa awarded contract at Royal Berkshire NHS Foundation
Trust
-- First direct commercial contract for Bleepa from the NHSx Clinical Communications Framework
-- Bleepa to be rolled-out in targeted clinical settings at the
Royal Berkshire NHS Foundation Trust as part of a one year
GBP84,000 contract
-- New Bleepa features to be released for the Trust: Virtual
Multi-Disciplinary Meetings, referral pathways and Photocapture to
securely share medical photographs
London, 24 March 2021: Feedback plc (AIM: FDBK, "Feedback" or
the "Company"), the specialist medical imaging technology company,
today announces it has been awarded a one year contract with a
value of GBP84,000 with the Royal Berkshire NHS Foundation Trust
("the Trust") for Bleepa, its flagship clinical communications
platform, across a number of targeted clinical settings. The
contract funding has been drawn down from the NHSx National
Clinical Communication Tool Framework.
The Royal Berkshire NHS Foundation Trust, which operates The
Royal Berkshire Hospital in Reading, is a leading healthcare
provider with an established track record of digital innovation.
The Trust is keen to evaluate Bleepa as part of its wider
communication strategy and is a frontrunner in recognising the need
to transition away from unregulated platforms such as WhatsApp for
clinical communication.
The Trust will have access to the latest features on the Bleepa
platform:
-- Feedback will work with the Trust to enhance Virtual
Multi-Disciplinary Meetings module (MDTs). MDTs are essential to
delivering streamlined patient care. However, the gathering of
specialist clinicians from different clinical settings to assess
patient cases is time consuming, costly and inefficient, with the
logistical complexities accentuated during the COVID-19 pandemic.
Bleepa supports a new way of running MDTs asynchronously and the
Bleepa image viewer function will enable each clinical participant
in the MDT to see imaging in the correct clinical quality,
something that cannot be achieved through screenshares on a video
call currently, ensuring regulatory compliance.
-- Photocapture has been in development by the Company for the
last three months and will form part of a planned product release,
version 1.3. The photocapture module enables clinicians to acquire
clinical images of patients, such as medical photographs of skin
lesions or wounds, where no patient data resides on the device
used. These photographs will be added to the Bleepa patient file
which can then be shared with clinical colleagues for discussion
and become part of the patient record. The Trust will provide a
clinical evaluation of the photocapture module which will form part
of the CE marking process for the new feature.
-- Feedback will also work with the Trust to evaluate the
referral module of the product, linking it to the existing workflow
for clinical, intra-Trust referral pathways embedded in the Trust's
Electronic Patient Record. As Bleepa referral management aligns
with clinical best practice and supports standardisation along the
patient pathway, it has the capability to improve clinical
communication.
The photocapture module will enable Bleepa to be used for a
wider range of services outside of this contract such as
dermatology services, community nursing and diabetes wound
management, allowing Bleepa to reach a wider clinical audience
outside of the secondary care setting, in a zero footprint way.
Investor Presentation
The Company is pleased to announce that Tom Oakley, CEO of
Feedback, will provide a live presentation relating to today's
announcement via the Investor Meet Company platform on Tuesday 30
March 2021 at 12:00pm BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via the Investor
Meet Company dashboard up until 9.00am BST the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Feedback plc via:
https://www.investormeetcompany.com/feedback-plc/register-investor
Investors who already follow the Company on the Investor Meet
Company platform will be automatically invited.
Dr Tom Oakley, CEO of Feedback, commented:
"We are delighted to be working with a Trust that has clearly
demonstrated a commitment to driving innovation for their
clinicians by providing a platform for secure digital medical
communications . This contract is recognition of the huge work that
has gone into making Bleepa the most reputable tool on the market
and clearly demonstrates product market fit. As we have seen in
previous clinical settings, Bleepa has the ability to streamline
the patient pathway and save clinicians time, no matter their
location, and we look forward to building a strong and successful
relationship with the Royal Berkshire NHS Foundation Trust."
Nigel Uwins, Assistant Director IT Support and Architecture at
the Royal Berkshire NHS Foundation Trust, commented:
"The Trust is excited to work with Feedback to implement and
utilise the capabilities of the Bleepa platform in a number of
areas. We were successful in obtaining NHSE funding for this work
and Bleepa were selected using the Clinical Communications
Framework. We have found Feedback very co-operative and are looking
forward to a successful partnership with them in the coming
months."
-Ends-
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated
Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas 07980 541 893 or 07748 325 236 or
Johnson 07884 664 686
Notes to editors
Feedback plc (AIM: FDBK) is a medical imaging technology
business. Its core product, Bleepa, is a revolutionary medical
imaging communications app, providing an easy-to-use, high quality
tool to enable remote and secure communications between front-line
clinicians and teams. Importantly, it is the only CE marked medical
imaging communications platform on the NHSx clinical communications
tools framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care facilitators. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of diagnosis.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTPPUCAWUPGGBW
(END) Dow Jones Newswires
March 24, 2021 03:00 ET (07:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024